Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Tempus AI drives growth with AI-powered diagnostics and data licensing despite recent stock drop.
TEM
$56.80
-$0.45 -0.79%

Tempus AI drives growth with AI-powered diagnostics and data licensing despite recent stock drop.

Analyst Insights
08 May 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Tempus AI, Inc. leverages AI and a large patient database to lead in precision medicine through genomic diagnostics and data licensing. Despite a 50% decline in share price and ongoing losses, the company shows rising revenues, expanding margins, and a strong contract pipeline valued at $1.1 billion. Its net retention rate of 126% and increased 2026 revenue guidance to around $1.6 billion highlight its growth potential. These factors support a strong buy rating for long-term investors focused on transformative healthcare technology.

More News (TEM)

Tempus AI's healthcare data segment revenue jumps 40% YoY, targeting $500M+ in 2026.

Tempus AI's healthcare data segment revenue jumps 40% YoY, targeting $500M+ in 2026.

Tempus AI, Inc. reported a 40% year-over-year increase in its healthcare data segment revenue for Q1 2026, reaching $87 million. This growth is driven by a surge in MRD testing volume, which rose 500% YoY due to a partnership with Personalis for a re...

Analyst Insights
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App